Dravet Syndrome Advances
Stoke Therapeutics Completes Phase 3 Enrollment for Zorevunersen in Dravet Syndrome
Anonymous
Key Points
1
The European cohort of roughly 30 patients is expected to have its last patient enroll in August 2026, with enrollment continuing in Europe alongside ongoing U.S., U.K., and Japan sites.
2
Stoke plans to complete a rolling NDA submission to the FDA in the second half of 2027, anchored by a Phase 3 data readout expected in Q3 2027.
3
Stoke highlights five years of clinical data for zorevunersen supporting ongoing development and potential disease-modifying effects in Dravet syndrome.
4
CEO Ian F. Smith framed the acceleration as reflecting the severity of Dravet syndrome and the potential of zorevunersen to address the underlying genetic cause, reducing seizure burden and supporting neurotypical development.
5
Stoke describes zorevunersen within the context of RNA medicines using its TANGO antisense oligonucleotide platform to restore protein expression.
Stoke Therapeutics has finished enrolling 162 patients in its Phase 3 EMPEROR study of zorevunersen for Dravet syndrome, the company announced June 30, 2026. The trial spans sites in the U.S., U.K., and Japan — and about 50 patients have already passed the critical 28-week treatment mark with zero dropouts, according to MarketScreener.
Stoke plans to begin a rolling FDA application in Q1 2027, with a full Phase 3 data readout expected in Q3 2027. If approved, zorevunersen would be the first drug to treat the underlying genetic cause of Dravet syndrome — not just its symptoms.
Zero Dropouts Signal Rare Confidence in Pediatric Trial
Enrollment closed in roughly 10 months — faster than the norm for rare disease trials. TipRanks noted that zero discontinuations among all 162 patients is an unusually strong signal in pediatric epilepsy research. Analysts called it "steady execution." The speed also reflects how desperate families are for a better option: Dravet syndrome affects about 1 in 16,000 births in the U.S., or around 16,000 patients nationwide, according to GuruFocus.
CEO Ian F. Smith said the pace reflects the stakes. "The rapid enrollment reflects the severity of Dravet syndrome and the potential of zorevunersen to address the underlying genetic cause," he said, "resulting in reduced seizure burden and the opportunity for more neurotypical development." About 30 more patients in Europe are expected to finish enrolling by August 2026, though that cohort will not be part of the U.S. FDA filing.
How Zorevunersen Targets the Root Cause, Not Just Seizures
Most Dravet syndrome treatments only manage seizures. Zorevunersen works differently. It uses Stoke's TANGO platform — short for Targeted Augmentation of Nuclear Gene Output — to boost protein output from the one healthy copy of the SCN1A gene that patients retain. The mutated copy produces only half the normal protein, leaving the brain's electrical system unstable, according to GuruFocus.
This approach is not gene therapy. It does not replace or edit a gene. Instead, it uses an antisense oligonucleotide — a short synthetic molecule — delivered via lumbar puncture to turn up production from the working gene. In March 2026, the New England Journal of Medicine published Phase 1/2a data showing durable seizure reduction and cognitive gains over 24 months, which MarketScreener reported as a landmark moment for the field.
FDA Filing Road Map: Rolling NDA Starts in Early 2027
Stoke's regulatory path is built for speed. The company will begin a rolling NDA submission to the FDA in Q1 2027. That means it can submit completed sections of its application before all data is final. The full Phase 3 readout — measuring change in major motor seizure frequency over 28 weeks — is set for Q3 2027. The complete NDA submission is expected in the second half of 2027, according to MarketScreener.
The FDA has already granted zorevunersen three key designations: Breakthrough Therapy, Orphan Drug, and Rare Pediatric Disease. Each one speeds up review and lowers regulatory hurdles. A potential U.S. commercial launch could follow as early as 2028. Biogen holds rights to sell the drug outside the U.S., Canada, and Mexico.
Competitors and Caution Clouds an Otherwise Strong Picture
Stoke is not alone in the race. Encoded Therapeutics is testing ETX101, a gene-regulation therapy delivered via AAV9 viral vector, in its own Phase 3 POLARIS program. Gene therapies offer a potential one-time treatment but carry risks like liver toxicity. Zorevunersen requires repeat lumbar punctures but can be adjusted or stopped if problems arise — a key difference for risk-averse families and doctors.
On the financial side, TipRanks rates the stock as neutral based on technical signals, even as some analysts set price targets as high as $39.00 per share. GuruFocus flags the stock as potentially overvalued given the company's cash burn. Stoke's market cap sits near $2 billion — reflecting both the promise of a first-in-class therapy and the uncertainty that comes before any Phase 3 readout.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
10
Articles
19
Reach
29
A
AnonymousAuthor
